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A new generation of bispecific anti-HIV-1 antibodies combines the breadth and potency of previous broadly neutralizing antibodies in a synergistic manner, producing enhanced in vitro viral neutralization and better control of viremia in vivo.
INTRODUCTION
Recent development and characterization of antibodies against the envelope glycoprotein of HIV-1 (Env) with broad and potent neutralizing activity suggested their passive administration as an effective strategy for the prevention or treatment of HIV-1 infection in humans (Burton and Mascola, 2015; Klein et al., 2013) . Indeed, a number of recent studies in murine and non-human primate models of HIV-1 infection (Barouch et al., 2013; Bournazos et al., 2014; Halper-Stromberg et al., 2014; Horwitz et al., 2013; Klein et al., 2012b; Shingai et al., 2013) , as well as in HIV-1-infected humans, showed that broadly neutralizing anti-Env antibodies (bNAbs) have the capacity to confer both effective pre-exposure prophylaxis and therapeutic control of viremia (Caskey et al., 2015; Lynch et al., 2015) . In contrast to conventional antiretroviral pharmacologic strategies, HIV-1 control by anti-Env bNAbs is mediated by pleiotropic effector functions, including viral neutralization and clearance, elimination of HIV-1-infected cells, and stimulation of host immune responses and induction of long-term immunity (Barouch et al., 2013; Bournazos et al., 2014 Haigwood et al., 2004; Halper-Stromberg et al., 2014; Ng et al., 2010; Pietzsch et al., 2012) .
Despite the profound benefits of anti-Env bNAb therapy for the control of HIV-1 infection, two main limitations exist: (1) no single bNAb has the capacity to efficiently neutralize all virus strains, and (2) bNAb administration is often associated with the emergence of virus escape mutants in the respective bNAbtargeting epitope (Diskin et al., 2013; Horwitz et al., 2013; Klein et al., 2012b) . Co-administration of two or more bNAbs with non-overlapping epitope specificities is, therefore, necessary to overcome these limitations and confer robust control of HIV-1 replication (Klein et al., 2012b) . Indeed, previous studies in murine models of HIV-1 infection indicated that the use of single bNAbs is inadequate for effective control of virus replication, as the administered bNAb often exerts significant selection pressure on the virus, leading to the rapid generation of escape mutants (Diskin et al., 2013; Horwitz et al., 2013; Klein et al., 2012b) . These limitations suggest the development of a new class of antibody-based molecules that would combine the breadth, potency, and antigenic specificity of two bNAbs required for the effective control of HIV-1 infection. Indeed, bispecific anti-Env bNAbs (biNAbs) represent an attractive strategy for the prevention and treatment of HIV-1 infection, as they offer unique advantages over conventional, monospecific antibodies, providing a compelling platform for the development of single therapeutic molecules with improved in vivo protective activity.
Recent attempts to generate anti-HIV-1 bispecific antibodybased molecules mainly focused on targeting HIV-1-infected cells through the use of anti-Env specificities combined with anti-CD3 (Pegu et al., 2015; Sung et al., 2015) , a concept originally developed for anti-tumor bispecific molecules (Chames and Baty, 2009 ). This approach induces clearance of HIV-1-infected cells by increasing the recruitment of cytotoxic T cells to Env-expressing infected cells, promoting their lysis. Since these molecules specifically target infected cells without any direct effects on virus neutralization, their use in prophylactic regiments to block HIV-1 infection is rather limited. Additionally, (A) Overview of the strategy for generating biNAbs to ensure proper pairing of the heavy and light chains and heterodimerization. For correct heavyand light-chain pairing, one of the parental mAbs was expressed in the CrossMab format (CH1-CL swapping), while for the other mAb, the wild-type domain architecture was maintained. Heavy-chain heterodimerization was achieved by the introduction of point mutations in the CH3 domain of the two mAbs.
(B and C) Binding specificity for gp140 (B) and in vitro neutralization activity of wild-type and CrossMab variant of 10-1074 (C) were assessed by ELISA using recombinant gp140 and standardized TZMbl neutralization assay, respectively. No difference in the antigen specificity and in vitro neutralization activity was noted between the different 10-1074 mAb variants. A 450 , absorbance at 450 nm.
(D-F) ELISA assays to determine dual specificity of the 3BNC117/10-1074 biNAb. (D) Competition ELISA with increasing concentrations of each of the parental bNAbs or a mixture (1:1) of the two bNAbs to determine dual specificity of the biNAb. (E) The 3BNC117/10-1074 biNAb and the 3BNC117 and 10-1074 bNAbs were immobilized to gp140-coated microtiter plates and detected using Fc domain-or light-chain (k or l) subclass-specific secondary IgG. The biNAb was detected with both the anti-kappa and anti-lambda secondary antibodies, whereas 3BNC117 and 10-1074 were detected only with anti-kappa or anti-lambda, respectively. (F) Epitope-specific ELISA using a CD4bs antigen (2-CC Core) for capture and an anti-lambda detection antibody to confirm bispecific activity. Data are represented as means ± SEM.
(legend continued on next page) despite the reported low toxicity of these molecules, targeting host receptors like CD3 still poses concerns over the long-term safety of this approach, especially in HIV-1-infected, immunocompromised individuals. In addition, such molecules exhibit a relatively short half-life, as their interaction with host cells enhances their clearance from circulation. Likewise, limitations associated with targeting host receptors (e.g., toxicity, enhanced clearance) are also expected for anti-CD4/anti-Env bispecific antibodies (Pace et al., 2013) . Therefore, we aimed to develop and characterize biNAbs targeting exclusively the HIV-1 Env trimer, focusing particularly on the optimization of these biNAbs to exhibit significantly improved, neutralization activity, compared to unmodified, monospecific bNAbs. Although several strategies have been previously described for the generation of antibodies or antibody-based molecules with dual specificities (Spiess et al., 2015) , in the present study, a major prerequisite for the development of anti-HIV-1 Env biNAbs was to maintain the physiological immunoglobulin G (IgG) architecture, thereby preserving the favorable pharmacokinetic properties of IgG (half-life of 3 weeks for human IgG1) and its Fc effector function, which has been previously shown to contribute to the in vivo protective activity of anti-HIV-1 bNAbs Halper-Stromberg et al., 2014; Hessell et al., 2007) . Previous attempts to generate anti-HIV-1 Env biNAbs based on the IgG1 structure yielded biNAbs with high breadth and potency, as well as sufficient in vivo stability and half-life . However, none of these anti-Env biNAbs exhibited improved neutralization potency compared to their respective parental bNAbs, suggesting that IgG1 biNAbs offer no advantages over conventional, monospecific bNAbs .
We therefore aimed to generate anti-Env biNAbs with improved neutralization potency by exploiting the unusual structure of the IgG3 hinge domain engineered to increase Fab domain flexibility, thereby favoring hetero-bivalent interactions with the Env trimer. Using this strategy and a panel of bNAbs targeting distinct epitopes on the HIV-1 Env, we have generated and characterized the in vitro neutralization activity of several biNAb combinations, identifying particular biNAbs with evidence for synergistic activity i.e., exhibiting increased neutralization potency compared to their respective parental, monospecific bNAbs. These hinge-domain-engineered biNAbs exhibited improved neutralization potency and enhanced in vivo protective activity in HIV-1-infected humanized mice, suggesting their potential clinical use for the control of HIV-1 infection in humans.
RESULTS

Generation and Characterization of Anti-HIV-1 biNAbs
To study the activity of anti-Env biNAbs, we initially selected two monoclonal antibodies (mAbs) with broad and potent in vitro and in vivo activity: 3BNC117 (Scheid et al., 2011 ) and 10-1074 (Mouquet et al., 2012 , which target the CD4-binding site (CD4bs) and the V3 sites of Env, respectively. For the generation of 3BNC117/ 10-1074 biNAbs, we used a combination of previously described strategies (Merchant et al., 1998; Ridgway et al., 1996; Schaefer et al., 2011) to ensure the proper pairing of the heavy and light chains of the two parental mAbs and generation of heavy-chain heterodimers ( Figure 1A) . Pairing of the correct heavy chain with the respective light chain was achieved by swapping the CH1 domain with the constant domain of the light chain (CL) for one mAb (10-1074) while preserving the wild-type domain organization for the other mAb (3BNC117) (Schaefer et al., 2011) . This approach (CrossMab; Schaefer et al., 2011) had no measurable effect on the antigenic specificity and neutralization activity of the 10-1074 mAb, as determined by antigen (gp140)-specific ELISA and TZMbl-based in vitro neutralization assay (Montefiori, 2005) against an extended multiclade virus panel, respectively ( Figures 1B and 1C) . Heterodimerization of the heavy chain was achieved by introducing mutations into the CH3 domain that alter the physical and chemical properties of the two mAb heavy chains, favoring heterodimer formation (Merchant et al., 1998; Ridgway et al., 1996) . Consistent with previous reports Merchant et al., 1998) , this approach resulted in efficient expression of biNAbs, typically yielding >90% heterodimers. By taking advantage of the differences in the light-chain isotype (k for 3BNC117 and l for 10-1074) and the Env epitope specificity (CD4bs and V3 for 3BNC117 and 10-1074, respectively), competition and epitope-specific ELISA assays confirmed the dual specificity of the resulting 3BCN117/10-1074 biNAb ( Figures 1D-1F ).
IgG1 biNAbs Exhibit Reduced Neutralization Potency Compared to Their Respective Parental bNAbs
Using a standardized TZMbl assay (Montefiori, 2005) , evaluation of the in vitro neutralization activity of the 3BNC117/ 10-1074 biNAb against an extended multiclade virus panel revealed a marginal increase in the neutralization breadth over 3BNC117 and 10-1074 bNAbs ( Figure 1G ; Table S1 ). However, neutralization potency was markedly reduced when compared to the activity of the parental bNAbs (either alone or as a mix, calculated based on the lowest IC 50 (half maximal inhibitory concentration) titer of the two bNAbs for a given virus). For the majority of the viruses tested, the observed IC 50 titers of the biNAb were the average from the two parental bNAbs (Table S1 ). To determine whether the observed reduction in the neutralization potency was related to the epitope specificity of the selected bNAbs, we extended our study by focusing on different regions of Env, including the V1/2 epitope (targeted by the PG16 bNAb; Walker et al., 2009) , the V3 epitope (targeted by the 10-1074; Mouquet et al., 2012) , PGT121 and PGT128 bNAbs Walker et al., 2011) , and antibodies against the gp120/41 interface (PGT151) (Blattner et al., 2014) and 35O22 (Huang et al., 2014) . Similar to the 3BNC117/10-1074 combination, V1/2-V3 (G) In vitro neutralization breadth and potency plot of 3BNC117/10-1074 IgG1 biNAb against an extended (120 strain) multiclade virus panel. Neutralization activity of their respective parental IgG1 bNAbs was included for comparison. The 3BNC117/10-1074 IgG1 biNAb exhibited marked reduction in neutralization potency compared to the activity of a mix of their parental mAbs (determined based on the activity of the most potent parental mAb for a given virus strain) See also Table S1 .
biNAbs (PG16/10-1074, PG16/PGT121, and PG16/PGT128), as well as the gp120/41 interface biNAb, PGT151/35O22, exhibited compromised neutralization potency and none of the combinations achieved the activity of their respective parental bNAbs (Figures 2A-2D; Tables S2, S3 , S4, and S5). These findings clearly suggest that biNAbs, regardless of their epitope specificities, fail to recapitulate the neutralization activity of their respective parental bNAbs, offering no advantages over conventional, monospecific bNAbs.
Generation and Evaluation of IgG Hinge Domain Variants
Based on the IgG3 Hinge Structure A key immune evasion mechanism of HIV-1 against host antibody responses is the remarkably low density of Env molecules on the viral surface (Zhu et al., 2006) , as well as the unique Env trimeric architecture, which precludes high-avidity bivalent interactions of IgG (Klein and Bjorkman, 2010) . It is, therefore, likely that the tested biNAbs would exhibit predominantly monovalent binding to their respective epitopes, possibly accounting for the lack of synergistic activity. Indeed, given the relative rigidity and the short length of the hinge domain of IgG1, concurrent binding of the two Fab arms within the same Env trimer is largely restricted. Overcoming this limitation and favoring intra-trimeric, bivalent interactions of biNAbs should augment their neutralization activity through enhanced avidity (Galimidi et al., 2015; Klein and Bjorkman, 2010; Klein et al., 2009) . Among the human IgG subclasses, IgG3 encompasses an exceptionally long and flexible hinge domain, with distinct structural and functional characteristics (Roux et al., 1997 (Roux et al., , 1998 (Figure 3A ). It comprises a 17mer amino acid sequence followed by three 15mer repeats that are highly homologous to the IgG1 hinge structure and represent genomic duplication events of the ancestral hinge-encoding exon, conserved among all other IgG subclasses (Roux et al., 1998) . Previous biophysical studies on the IgG3 hinge indicated that the hinge domain spans a distance of over 110 Å , and the unique primary amino acid composition of the CH1 proximal 17mer confers increased flexibility of the Fab arms, allowing for greater degree of rotation compared to IgG1 (117  versus  136 ) (Roux et al., 1998) . Based on these unique properties of the IgG3 hinge domain structure, we aimed to develop biNAbs with increased Fab domain flexibility, using the IgG3 hinge as template. To further increase the inherent IgG3 hinge flexibility, we generated an ''open'' IgG3-based hinge variant (IgG3CÀ), in which all the cysteine residues have been replaced with serines with the exception of the last two, CH2 proximal residues that are necessary to maintain the structural integrity of the Fc domain through inter-heavy-chain disulfide bonding ( Figure 3A ). Hinge domain variants of 10-1074 IgG1 were expressed as chimeric molecules, in which the wild-type hinge domain (IgG1) was replaced with that of either IgG3 or the IgG3CÀ variant. With the exception of the hinge domain, all other domains of the constant region (CH1, CH2, and CH3) were of the IgG1 subclass to preserve the effector function and half-life of wild-type IgG1. Indeed, hinge domain variants of 10-1074 demonstrated comparable binding affinity to the different classes of human and mouse Fcg receptors (FcgRs), suggesting a minimal role for the hinge region in Fc-FcgR interactions ( Figure S1C ). Likewise, no differences among the hinge domain variants were noted in terms of protein stability and in vivo pharmacokinetics ( Figure 3B ; Figures S1A and S1B).
BiNAbs with Engineered Hinge Domain Structures Exhibit Improved Neutralization Activity
Having established that modifications in the hinge domain had no impact on FcgR binding or on IgG half-life and stability, we assessed the neutralization activity of 3BNC117/10-1074 biNAb hinge variants in TZMbl assays (Montefiori, 2005) against an extended multiclade virus panel. Compared to the wild-type, unmodified IgG1 biNAb, the IgG3CÀ hinge variant of the 3BNC117/ 10-1074 biNAb presented improved activity ( Figures 3C and 3D biNAb (IC 50 : 0.242 mg/ml versus 0.110 mg/ml; IC 80 : 0.717 mg/ml versus 0.388 mg/ml for IgG1 versus IgG3CÀ, respectively). In addition, the observed neutralization breadth and potency of the IgG3CÀ biNAb was comparable to that expected from the mix of the two parental antibodies ( Figure 3C ; Table S6 ). Indeed, whereas IgG1 biNAb exhibited the average neutralization potency of the two parental bNAbs (3BNC117 and 10-1074), IgG3CÀ biNAb demonstrated activity equal to, or in some cases better than, that of the parental bNAbs ( Figure 3D ). In contrast, no difference in the neutralization activity was noted among hinge domain variants of the parental, monospecific antibodies (3BNC117 and 10-1074), demonstrating activity similar to that of their wild-type IgG1 counterparts ( Figures S2A and S2B ). These findings indicate that alterations in the Fab arm flexibility through modifications in the hinge domain structure lead to improved In vivo stability and half-life was compared between the various 10-1074 hinge-domain variants (means ± SEM, n = 4 mice per group). No differences among the hinge domain variants were noted in terms of in vivo pharmacokinetics and protein stability (see also Figure S1 ). Figure S1 and Table S6. neutralization activity of biNAbs, suggesting that hinge structures engineered for increased length and flexibility could lead to the development of biNAbs with enhanced breadth and potency.
Evaluation of the Neutralization Activity of a Panel of HingeModified biNAbs Reveals Particular Combinations with Synergistic Activity Given the intrinsic flexibility of the Env trimer (Ward and Wilson, 2015) , as well as the differences in the angle and orientation by which the Fab domains of antibodies target their respective epitopes on Env, it is difficult to accurately predict the distance required for two Fab arms of a biNAb combination to preferentially exhibit bivalent, intra-trimeric binding and, thus, confer synergistic activity. To add to this complexity, there are multiple examples of bNAbs that recognize conformational epitopes on Env or inhibit recognition by other bNAbs upon binding, either by inducing structural changes to the Env trimer or by steric inhibition mechanisms (Burton and Mascola, 2015; Derking et al., 2015; Julien et al., 2013; Ward and Wilson, 2015) . In an attempt to identify particular biNAb combinations that would exhibit synergistic activity, a panel of bNAbs targeting various distinct epitopes on the Env trimer with different angles and orientations (Burton and Mascola, 2015) was selected: 3BNC117 (Scheid et al., 2011), CH103 (Liao et al., 2013) , and 8ANC131 for CD4bs; PG16 (Walker et al., 2009 ), PGT145 , and PGDM1400 (Sok et al., 2014) for V1/2, 10-1074 (Mouquet et al., 2012); PGT121, PGT128 Walker et al., 2011) , and PGT135 (Kong et al., 2013) for V3, PGT151 (Blattner et al., 2014) ; 3BC176 (Klein et al., 2012a; Lee et al., 2015) and 8ANC195 (Scharf et al., 2015) for the gp120/gp41 interface; and 10E8 (Huang et al., 2012) for MPER ( Figure 4A ). These bNAbs were cloned as IgG3CÀ hinge domain variants, and biNAbs were generated with non-overlapping epitope specificities. As we have previously described for 3BNC117 and 10-1074 bNAbs, no difference in the neutralization activity was observed between IgG1 and IgG3CÀ hinge variants for all the parental, monospecific antibodies ( Figure S2 ; data not shown). Analysis of the neutralization activity of the various biNAb combinations against a panel of seven cross-clade, tier 2/3 viruses identified particular combinations exhibiting higher (synergistic), equal (neutral), or lower (inhibitory) activity compared to their respective parental bNAb counterparts (also in the IgG3CÀ hinge variant format) (Figures 4B and 4C ; Table S7 ).
Three particular biNAb combinations that showed evidence for synergistic activity were selected for further analysis, based on their epitope specificities, evidence for efficient expression, sufficient in vivo half-life, and long-term protein stability. These combinations included: PGT151/10-1074, 8ANC195/PGT128, and 3BNC117/PGT135 biNAbs. Evaluation of their neutralization activity against an extended multiclade virus panel revealed that the 8ANC195/PGT128 biNAb combination presented a modest improvement in activity, while no differences were noted for the PGT151/10-1074 biNAb (Figures 5A and 5B ; Tables S8  and S9 ). In contrast, the 3BNC117/PGT135 biNAb exhibited augmented neutralization breadth and potency, surpassing the activity of the parental bNAbs (3BNC117 and PGT135) ( Figures  5C and 5D ; Table S10 ). For the vast majority of the tested virus strains (119 strains), the 3BNC117/PGT135 biNAb demonstrated lower IC 50 and IC 80 titers compared to the most potent of the parental bNAbs (3BNC117 or PGT135) for each tested virus strain. Overall, the 3BNC117/PGT135 IgG3CÀ biNAb was capable of neutralizing over 93% of the tested viruses, with an average (geometric mean) IC 50 of 0.036 mg/ml, representing one of the most potent anti-HIV-1 Env antibodies characterized so far.
The Synergistic Neutralization Activity of the 3BNC117/ PGT135 biNAb Is Dependent on Hinge Length and Flexibility The synergistic activity observed for the 3BNC117/PGT135 IgG3CÀ biNAb might actually reflect the capacity of this biNAb combination for bivalent binding of the two Fab arms accomplished by the flexible IgG3CÀ hinge structure. Indeed, comparison of the gp120-bound PGT135 Fab crystal structure to other anti-V3 bNAbs (PGT122 or PGT128) revealed a unique orientation and angle for PGT135 (Kong et al., 2013) Table S7. that, when combined with the 3BNC117 bNAb, as in the case of the 3BNC117/PGT135 IgG3CÀ biNAb, would facilitate intratrimeric bivalent interactions ( Figures 6A and 6B) , as the length and flexibility of the IgG3CÀ hinge could sufficiently span the distance between the two Fab arms bound to the Env trimer. To test this assumption and provide additional mechanistic insights into the requirements for the enhanced synergistic neutralization activity of the 3BNC117/PGT135 IgG3CÀ biNAb, we assessed the in vitro neutralization activity of different hinge domain variants with variable lengths and properties.
3BNC117/PGT135 biNAbs and their respective parental bNAbs (3BNC117 and PGT135) were expressed as variants encompassing the hinge domain structure of wild-type IgG1, IgG3, or IgG3CÀ (open hinge structure based on wild-type IgG3 sequence), and their neutralization activity was assessed against a multiclade, 20-strain panel. When the activity of a 1:1 mix of the two parental bNAbs was compared among the different hinge domain variants, no significant differences were noted, with all the hinge variants exhibiting comparable neutralization activity ( Figures 6C and 6D ). In contrast, 3BNC117/PGT135 biNAb demonstrated significantly augmented activity only in the IgG3CÀ, but not in the IgG1 or IgG3, hinge Tables S8, S9 , and S10. Predicted neutralization activity of the mix of the two parental bNAbs (determined based on the activity of the most potent parental mAb for a given virus strain) was included for comparison. (D) Representative IC 50/80 titers (in micrograms per milliliter) of bNAbs 3BNC117 and PGT135 and the 3BNC117/PGT135 biNAb showing substantially improved neutralization activity of the biNAb over the parental bNAbs. See also Tables S8, S9 , and S10. domain format, indicating that the synergistic activity of the 3BNC117/PGT135 biNAb is dependent upon the unique structure and flexibility of the IgG3CÀ hinge variant. To provide further evidence on the role of the hinge length in the improved neutralization activity of the 3BNC117/ PGT135 biNAb, two different variants of the IgG3CÀ hinge structure were generated that lacked either one (-15mer) or two (-2315mer) of the three 15 amino acid repeats (EPKSSDTPPPSPRSP) that constitute part of the IgG3CÀ hinge sequence ( Figure 3A ). 3BNC117/ PGT135 biNAbs encompassing the shortened hinge domain variants were generated, and their activity was compared to that of IgG3CÀ. Assessment of the in vitro neutralization activity revealed that hinge length is correlated with the neutralization potency of the 3BNC117/PGT135 biNAb, with shorter hinge variants (À15mer or À2315mer) exhibiting impaired neutralization activity ( Figures 6E and 6F ). These findings suggest that the observed enhancement in the in vitro neutralization activity of the 3BNC117/PGT135 biNAb is dependent upon hinge length and flexibility, which likely favor intratrimeric, bivalent Env interactions.
3BNC117/PGT135 IgG3CÀ biNAb Confers Enhanced In Vivo Protective Activity in HIV-1-Infected Humanized Mice
In order to determine whether the observed increase in neutralization potency of the 3BNC117/PGT135 IgG3CÀ biNAb also translates to improved therapeutic efficacy in vivo, we evaluated its capacity to suppress viremia in humanized mice (human CD34 + -reconstituted NRG mice) (Klein et al., 2012b) with established HIV-1 infection. HIV-1-infected humanized mice were treated either with a mix (1:1) of 3BNC117 and PGT135 bNAbs or with 3BNC117/PGT135 biNAb (all in IgG3CÀ hinge variant format). Among the two experimental groups, no differences in the in vivo half-life or the serum antibody levels were noted (Figures S3A and S3B) . Quantitation of plasma viremia revealed that 3BNC117/PGT135 biNAb treatment decreased viremia by an average of 1.5 log 10 during the treatment period ( Figures 7B-7D) , with the majority (seven out of nine) of treated animals exhibiting substantially reduced plasma viremia levels (D log 10 viremia < À1.0).
Mice that failed to demonstrate robust response to biNAb therapy were often associated with mutations in the biNAb-targeting epitopes (V3 or CD4bs; Figures S3C and S3D) . In contrast, administration of the 3BNC117 + PGT135 bNAb mix had a minimal effect on plasma viremia (mean Dlog 10 viremia: 0.15; Figures 7A, 7C , and 7D). These findings suggest that the 3BNC117/PGT135 IgG3CÀ biNAb represents a unique biNAb molecule with in vivo therapeutic activity, with the potential for future pre-clinical development.
DISCUSSION
Several recent studies using anti-Env antibodies with broad and potent neutralizing activity revealed their capacity to confer both effective pre-exposure prophylaxis and therapeutic control of viremia in murine and non-human primate HIV-1 disease models, as well as in HIV-1-infected humans (Barouch et al., 2013; Bournazos et al., 2014; Caskey et al., 2015; Halper-Stromberg et al., 2014; Horwitz et al., 2013; Klein et al., 2012b; Lynch et al., 2015; Shingai et al., 2013) . Studies on animal models for HIV-1 infection suggested that sustained therapeutic viremia suppression is accomplished by co-administration of a cocktail of bNAbs targeting key epitopes on the HIV-1 Env that are essential for viral fitness, thereby overcoming the emergence of virus escape mutants. Bispecific anti-HIV-1 Env antibodies represent an ideal therapeutic approach that would combine the breadth, antigenic specificity, and neutralization potency of two bNAbs into a single molecule, facilitating preclinical evaluation and development. In addition to the additive effect on the neutralization breadth, favoring hetero-bivalent interactions of the two Fab arms could confer synergistic activity (Klein et al., 2009 ), yielding biNAbs with substantially improved neutralization potency compared to conventional bNAbs. Indeed, the use of DNA-and proteinbased structures to link two Fab arms at optimal distances necessary to achieve hetero-bivalent, intra-trimeric interactions resulted in enhanced in vitro neutralization potency (Galimidi et al., 2015) . Based on these observations, we developed and characterized biNAbs with non-overlapping epitope specificities to identify particular biNAb combinations that would demonstrate potent and synergistic neutralization activity. Given the significance of the FcgR-mediated pathways in the in vivo protective activity of anti-HIV-1 bNAbs Halper-Stromberg et al., 2014; Hessell et al., 2007) , our major goal was to generate biNAbs with the wild-type IgG structure, while avoiding irregular, non-physiological architectures used in the past (Spiess et al., 2015) . This approach ensured that the resulting biNAb would have the capacity to interact with FcgRs and exhibit long and stable in vivo pharmacokinetics, with minimal immunogenicity potential. Indeed, all the generated biNAb variants exhibited identical in vivo half-life and affinity for the different classes of FcgRs. Attempts to generate anti-HIV-1 Env biNAbs based on the IgG1 structure were generally characterized by lower neutralization potency compared to their corresponding parental bNAbs, regardless of their epitope specificity (Figures 1G and 2; Tables S1, S2 , S3, S4, and S5). Similar findings have also been reported in a recent study that generated and characterized a number of anti-Env IgG1 biNAbs , suggesting that IgG1 biNAbs offer no advantages over conventional, monospecific bNAbs. Since the observed impairment in the neutralization potency possibly reflects the lack of sufficient flexibility of the two Fab arms to achieve bivalent, intra-trimeric interactions in the IgG1 format, hingedomain-engineered biNAbs were generated with improved Fab domain flexibility, based on the naturally occurring hinge domain of IgG3, which is characterized by a uniquely long and flexible structure (Roux et al., 1997 (Roux et al., , 1998 . This approach incorporates minimal changes to the overall IgG structure while it achieves significant enhancement in the neutralization breadth and potency. Among all the tested hinge-engineered biNAb combinations, 3BNC117/PGT135 showed evidence for synergistic activity, surpassing the potency of both parental bNAbs (3BNC117 and PGT135). Indeed, assessment of its neutralization potency indicated that, for the vast majority of the tested viruses, the 3BNC117/PGT135 biNAb exhibits lower IC 50 and IC 80 titers, and for over a third of the tested viruses, the improvement in the neutralization potency exceeded 10-fold compared to 3BNC117 and PGT135 bNAbs. Its enhanced activity was largely attributed to the hinge length and flexibility, as hinge domain variants with shorter length or decreased flexibility also exhibited reduced neutralization breadth and potency. These findings indicate that the improved neutralization activity of the 3BNC117/PGT135 IgG3CÀ biNAb is likely the result of bivalent, intra-trimeric interactions, accomplished by the unique structure of the engineered hinge domain of the IgG3CÀ variant. As previously suggested (Galimidi et al., 2015) , intra-trimeric, heterobivalent crosslinking of the two Fab arms increases the overall avidity of the Env trimer-biNAb interaction, thereby leading to augmented neutralization potency.
Although several mechanisms of bNAb binding interference have been described, even for bNAbs with non-overlapping epitope specificities such as 3BNC117 and PGT135 , our findings suggest that the observed effect of the 3BNC117/PGT135 biNAb could not be attributed to conformational changes induced upon bNAb binding, as no change in the neutralization activity was evident for the mix of the two bNAbs (3BNC117 + PGT135) ( Figures 6C and 6D ). However, a recent study that analyzed the binding profile of a panel of bNAbs to the soluble native BG505.SOSIP.664 gp140 trimer revealed that PGT135 unidirectionally inhibited the binding of antiCD4bs, VRC01-like antibodies to the gp140 trimer, due to reorientation of a glycan structure (predominantly Asn386 and/or Asn392 glycans), partly occluding the CD4bs epitope . Since all VRC01-like bNAbs exhibit substantially higher affinity for Env compared to PGT135, it is unlikely that such cross-bNAb inhibition would occur for strains sensitive to both bNAbs. Based on these findings, in the context of the 3BNC117/PGT135 biNAb, it is expected that, for virus strains sensitive to 3BNC117, increased neutralization potency would be expected through initial binding of the 3BNC117 arm (due to higher affinity) followed by the PGT135. In contrast, for viruses that are resistant to 3BNC117 but sensitive to PGT135, no improvement in the neutralization activity is expected due to PGT135-mediated occlusion of the CD4bs epitope. Indeed, (C and D) Comparison of viremia levels (C) or change from baseline at the end of the treatment period (D) revealed significant differences between the mix-and biNAb-treated mice (**p < 0.005; means ± SEM, n = 7 or 9). See also Figure S3 .
assessment of the extended panel neutralization data (Table  S10) indicates that, for the few virus strains that are resistant to 3BNC117 but sensitive to PGT135 (like CNE20, CNE21, X2088_c9), no enhanced neutralization activity is evident for the 3BNC117/PGT135 biNAb, and the observed neutralization potency is lower than that of the PGT135 bNAb, further supporting the notion that the enhanced neutralization activity of the 3BNC117/PGT135 biNAb is the result of bivalent, intra-trimeric interactions.
Despite the augmented neutralization potency of the 3BNC117/ PGT135 IgG3CÀ biNAb, it was essential to determine whether its in vitro activity also translates to enhanced in vivo therapeutic efficacy. Therefore, we assessed its in vivo activity in HIV-1-infected humanized mice, a robust model that recapitulates human HIV-1 infection and has been systematically used in the past to accurately investigate the in vivo activity of bNAbs Diskin et al., 2013; Halper-Stromberg et al., 2014; Horwitz et al., 2013; Klein et al., 2012b) . Consistent with the in vitro findings, 3BNC117/PGT135 IgG3CÀ biNAb showed improved in vivo protective activity, probably reflecting its enhanced neutralization activity. However, a role for Fc effector functions in the in vivo protective activity of this biNAb could not be excluded. In addition to enhancing neutralization, hetero-bivalent biNAb binding to the Env trimer could also lead to more stable biNAb-Env interactions, thereby facilitating clearance of viral particles and infected cells through FcgR-mediated mechanisms.
Collectively, these findings suggest that the hinge-engineered 3BNC117/PGT135 biNAb represents one of the most potent anti-HIV-1 bNAbs developed to date, exhibiting high neutralization breadth and potency, as well as improved in vivo activity. To comparatively benchmark the activity of the 3BNC117/PGT135 biNAb with previously characterized bNAbs, its neutralization breadth and potency were compared to that of several bNAbs targeting distinct epitopes on gp140. As shown in Figure S4A , the 3BNC117/PGT135 biNAb displays increased neutralization potency, compared to the most potent bNAbs so far characterized, including VRC07, PGT121, and PG9 (using data reported in Kong et al. [2015] ). Additionally, to gain further insights on how the activity of this biNAb compares to physical combinations of bNAbs, we directly compared the activity observed in this study for 3BNC117/PGT135 biNAb with that previously reported for several bNAb combinations (Kong et al., 2015) . Compared to all two-bNAb combinations, the 3BNC117/PGT135 biNAb demonstrated higher neutralization activity, neutralizing >80% of viral strains with an IC 50 < 0.1 mg/ml ( Figure S4B ). Its potency was only marginally lower, compared to that observed for the three-bNAb combinations. This analysis provides a direct measure of the neutralization activity of the 3BNC117/PGT135 biNAb against other bNAbs and bNAb combinations, highlighting the improved potency of this biNAb over conventional, monospecific bNAbs.
In summary, the present study described an approach for the generation of anti-HIV-1 Env biNAbs with physiological IgG architecture, FcgR binding profile, and pharmacokinetic properties. Compared to conventional, monospecific bNAbs, biNAbs with hinge-domain-engineered structures exhibit potent neutralization activity with improved breadth and potency and enhanced in vivo activity. These unique advantages of hingedomain-optimized biNAbs represent a platform technology that can also be extended to other viral and cellular targets.
EXPERIMENTAL PROCEDURES
A detailed description of the Experimental Procedures is provided in the Supplemental Experimental Procedures section.
In Vitro Neutralization Assay
In vitro neutralization activity of antibodies was assessed against different HIV-1 envelope pseudoviruses, using a standardized TZMbl neutralization assay, as previously described (Montefiori, 2005) . For assessing the IC 50/80 titers of a mix of two bNAbs, antibodies were mixed at a ratio of 1:1 (experimental IC 50/80 ). Predicted (theoretical IC 50/80 ) neutralization activity of a mix of two mAbs was determined by selecting the lowest IC 50/80 titer of the two mAbs for a given virus. For combinations involving two mAbs with non-overlapping epitope specificities, theoretical IC 50/80 has been shown to be comparable to the neutralization activity of the experimental IC 50/80 (Kong et al., 2015) .
In Vivo Experiments
All in vivo experiments were performed in compliance with federal laws and institutional guidelines and have been approved by the Rockefeller University Institutional Animal Care and Use Committee. Humanized NRG mice were generated, as previously described (Klein et al., 2012b) . Mice with a measurable human CD45 + graft (10-15 weeks, males and females) were infected following intraperitoneal (i.p.) injection of HIV-1 T251À18 (180 ng p24). Viral load was quantified 3 weeks post-infection, and mice with viral loads >10 3 copies per milliliter were included in treatment experiments. Mice were randomly assigned to experimental groups, and both groups had comparable baseline average viremia levels. Antibodies (either 1 mg of 3BNC117/PGT135 biNAb or 1 mg of a 1:1 mix of 3BNC117 [0.5 mg] and PGT135 [0.5mg]) were subcutaneously (s.c.) administered, biweekly for 4 weeks. Each experimental group consisted of nine mice, a group size previously determined to sufficiently detect response to antibody therapy Klein et al., 2012b) . Plasma HIV-1 viral load was determined by qRT-PCR as previously described Klein et al., 2012b) .
Statistical Analysis
Results from multiple experiments are presented as means ± SEM. IC 50 titers are presented as geometric mean ± 95% confidence interval (CI). For comparison of the in vitro neutralization activity, a Kruskal-Wallis test was used to test for differences in the IC 50/80 titers, and where statistically significant effects were found, post hoc analysis using Dunn's multiple comparison test was performed. For the comparison of viremia between the two experimental groups, a Mann-Whitney non-parametric (twosided) test was used. Data were analyzed with GraphPad Prism software (Graphpad), and p values of <0.05 were considered to be statistically significant.
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Supplemental Information includes Supplemental Experimental Procedures, four figures, and ten tables and can be found with this article online at http:// dx.doi.org/10.1016/j.cell.2016.04.050.
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